Company Introduce
Tonggan Medical College was founded in December 2013 by Professor Zhou Ping, former Deputy Director of the Organ Transplantation Research Institute and Director of the Transplantation Laboratory at Tongji Hospital of Huazhong University of Science and Technology. It is engaged in the research and development of biological artificial liver treatment technology and related medical devices, new biological materials, cell therapy, and blood purification technology. Selected as Wuhan Gazelle Enterprise, National High tech Enterprise, Hurun Baifu China's Most Valuable New Star Enterprise, Optics Valley Entrepreneurship Tomorrow Star Enterprise, Wuhan City Listed Reserve Gold Seed Enterprise, Hubei Province Listed Reserve Gold Seed Enterprise. In December 2023, we received investment from Wenzhou state-owned assets and relocated to Wenzhou, renaming ourselves as Zhejiang Tonggan Medical Technology Co., Ltd. We plan to list on the main board of the Hong Kong Stock Exchange between June and September 2026. From 2013 to 2023, our company only did one thing: developed a biologically artificial liver with our own intellectual property rights. Through ten years of effort, we became the world's first biologically artificial liver that was approved for clinical use and achieved charging. In the next ten years, we will continue to develop our unique characteristics and become a leading industry cluster in cell therapy and blood therapy worldwide.
2013 year
Established in
11000 ㎡+
Each Standard Factory
5 个
National Production Base
75 %
R&D Personnel
20 Prize+
Honors and Recognition
37 Authentication+
Patent Certification Already
in Place
Zhejiang Tonggan Medical Technology Co., Ltd
Since 2013
2013
Established in December.
2015
Received angel round investment from Huahui Investment in July to conduct large-scale animal experiments at Tongji Hospital.
2016
Received Series A investment from Guangdong Yili Rehabilitation Fund in February. Starting Human Clinical Trials at Wuhan University Central South Hospital in August.
2018
Obtained Series A+financing from Wuhan Huafang Jianmin Medical Trend Fund in September.
2019
The last case enrolled in the human clinical trial completed in December.
2021
Completion and acceptance of the national expert group on the biological artificial liver project at Central South Hospital in June. In September, Zhongnan Hospital submitted an application for new medical technology registration to the Hubei Provincial Health Commission.
2022
In March, Hubei Provincial Health Commission issued a document to complete technical filing. Selected as a reserve gold seed enterprise for listing in Hubei Province in May. In June, signed a contract with Chongqing Biotech City to establish the Huaxi District Production Base of Bioartificial Liver and settle in Banan District, Chongqing City. In July, we received a B-round investment of 60 million yuan from Chongqing Biotech City and Shenzhen Rongtao, with a post investment valuation of 1.02 billion yuan.
2023
January: Won the first prize for scientific and technological inventions in Hubei Province. December: Renamed as Zhejiang Tonggan Medical Technology Co., Ltd. after receiving investment from Wenzhou State-owned Assets Investment.
2024
April: Completed the signing ceremony with Zhongnan Hospital.
2026
Expected to list on the Hong Kong Stock Exchange via IPO